Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
308.8 USD | +0.93% |
|
+3.32% | +7.08% |
Jun. 14 | Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto | DJ |
Jun. 14 | Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.08% | 164B | |
+50.87% | 803B | |
-5.76% | 351B | |
+19.42% | 324B | |
+11.42% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
-3.26% | 155B | |
-1.84% | 117B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Inc. Reaffirms Revenue Guidance for the Year 2022